KalVista: Prophylaxis Is Shrinking The Acute HAE TAM [Seeking Alpha]
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Seeking Alpha
Ekterly's commercial debut faces headwinds from new, highly effective prophylactic competitors, shrinking the addressable market for on-demand HAE treatments like KALV's drug. KALV's financials show a widened net loss and increased cash burn, prompting a $125 million convertible notes raise that signals ongoing funding uncertainty. With potential new competition and evolving HAE therapies, I maintain a cautious stance on KALV despite its conservative valuation near 1x peak sales. BrianAJackson/iStock via Getty Images Overview KalVista Pharmaceuticals' stock ( NASDAQ: KALV ) is off 25% since my rating downgrade to Hold in July 2025. My analysis followed the FDA approval for Ekterly—the first oral on-demand drug for hereditary angioedema (HAE). If you have any familiarity with biotechnology This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such pos
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.MarketBeat
- KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects [Yahoo! Finance]Yahoo! Finance
- KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... [Yahoo! Finance]Yahoo! Finance
- KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
KALV
Earnings
- 11/10/25 - Beat
KALV
Sec Filings
- 12/4/25 - Form 4
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- KALV's page on the SEC website